NEUROLEPTIC MALIGNANT SYNDROME: Liability in Nursing Practice
1993; Slack Incorporated (United States); Volume: 31; Issue: 2 Linguagem: Inglês
10.3928/0279-3695-19930201-06
ISSN1938-2413
Autores Tópico(s)Treatment of Major Depression
ResumoNEUROLEPTIC MALIGNANT SYNDROME: Liability in Nursing Practice D Thomas Blair, RN, C, MS, , and , RN, C, MS Alana Dauner, RN, C, MSN, , RN, C, MSN D Thomas Blair, RN, C, MS and Alana Dauner, RN, C, MSN Journal of Psychosocial Nursing and Mental Health Services, 2013;31(2):5–9Published Online:February 01, 1993https://doi.org/10.3928/0279-3695-19930201-06Cited by:3PDFView Full Text ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInRedditEmail SectionsMoreAddonizio, G. The pharmacologic basis of neuroleptic malignant syndrome. Psychiatric Ann I99l;21(3):152-I56. Google ScholarAddonizio, G., Susman. V.L., Roth. S.D. Symptoms of neuroleptic malignant syndrome in 82 consecutive patients. Am J Psychiatry 1986; 143:1587-1590. Google ScholarAddonizio. G., Susman, V.L., Roth. S.D. Neuroleptic malignant syndrome: Review and analysis of 115 cases. Biol Psvchiatry 1987;22:1004-1020. Google ScholarAmerican Nurses' Association. ANA standards of psychiatric and mental health nursing practice. Kansas City, MO: Author. 1982. Google ScholarAnderson, E.S., Powers. P.S. Neuroleptic malignant syndrome associated with clozapine use. J Clin Psychiatry 1991; 52:102-104. Google ScholarAnonymous. Neuroloptic malignant syndrome after a single dose of metoclopramide. Nurses Drug Alert 1986:10(7):54. Google ScholarAnonymous. Neuroleptic malignant syndrome follow up. Nurses Drug Alert 1986; 10(9):72. Google ScholarBeck, C.M., Rawlins. R.P., Williams, S.R. Mental health-Psychiatric nursing, 2nd ed. St. Louis: CV Mosby Co. 1984. Google ScholarBlair, D.T. Risk management for extrapyramidal symptoms. QRB 1990; 16:116-124. Google ScholarBlair, D.T., Dauner. A. Extrapyramidal symptoms are serious side effects of the antipsychotic and other drugs. Nurse Pracitioner 1992, 17(11):56-65. Google ScholarBoard of Nurse Examiners. Rules and regulations relating to professional nurse education licensure and practice. Texas Nurse Practice Act, Austin, Texas, 1989. Google ScholarCahill, C., Arana, G.W. Navigating neuroleptic malignant syndrome. Am J Nurs 1986; 6:671-673. Google ScholarCaroff, S. Neuroleptic malignant syndrome. J Clin Psychiatry 1980; 41:179-185. Google ScholarDas Gupta, K., Young, A. Clozapine-induced NMS. J Clin Psvchiatry 1991;52(3):105-107. Google ScholarDauner, A., Blair, D.T. Akathisia: When treatment creates a problem. J Psychosoc Nurs Ment Health Serv 1990; 28(10):13-18. Google ScholarGuze, B.H., Baxter. L.R. Neuroleptic malignant syndrome. N Engl J Med 1985; 313:163-166. Google ScholarHooper, J.F., Herren, C.K., Goldwasser, H. Neuroleptic malignant syndrome: Recognizing an unrecognized killer. J Psychosoc Nurs Ment Health Serv 1989; 27(7): 13-15. Google ScholarKeck, P.E., Pope. H.R., Cohen, B.M.. McElroy, S.L., Nierenberg, A.A. Risk factors for neuroleptic malignant syndrome: A case control study. Arch Gen Psvchiatry 1989; 46:914-918. Google ScholarKeck, P.E., Pope. H.R., McElroy, S.L. Haloperidol and neuroleptic malignant syndrome. Am J Psychiatry 1988; 145:654. Google ScholarKeepers, G.A., Casey, D.E. Clinical management of acute neuroleptic induced extrapyramidal symptoms. In Current psychiatric therapies. New York: Grune & Stratton, 1986. Google ScholarKoehler, P.J., Mirondolle, J.F. Neuroleptic malignant syndrome and lithium. Lancet 1988; 24:1499-1500. Google ScholarLanglow, J.R., Alarcon, R. D. Trimiprimineinduced neuroleptic malignant syndrome. J Clin Psychiatry 1989; 80:144-145. Google ScholarLevenson, J.L. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142:1137-1145. Google ScholarMasters, J.C., Spitler, R. Neuroleptic malignant syndrome. J Psychosoc Nurs Ment Health Serv 1986; 24(9): 10- 16. Google ScholarMazurek, M. F. Rosebush, P.I. Tardive dyskinesia and the law. Can J Psychiatry 1990; 35:573-574. Google ScholarMcEvoy, G.K. Central nervous system agents. In American Hospital Formulary Service, Drug Information. Bethesda, MD: American Society of Hospital Pharmacists Press, 1992. Google ScholarMiller, D.D., Sharafuddin, M.J.A., Kathol, R.G. A case of clozapine induced neuroleptic malignant syndrome. J Clin Psvchiatrx 1991; 52:99-101. Google ScholarMiller, F., Menninger, J. Lithium-neuroleptic neurotoxicity is dose dependent. J Clin Psychopharmacol 1987; 7:89-91. Google ScholarMills, M.J., Spencer, E. Legal liability with psychotropic drug use: Extrapyramidal symptoms and tardive dyskinesia. J Clin Psychiatry 1987;48:28-33. Google ScholarMorrow, PL., Thompson, J.G., Cunningham, J.M. To bedlam and back. J Psychosoc Nurs Ment Health Serv 1986; 24(9): 17-20. Google ScholarPhysicians Desk Reference. Oradell, NJ: Medical Economics Company, Inc., 1985. Google ScholarPope, H.C., Cole, J.O. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986; 174:493-495. Google ScholarPope, H.C., Keck, P.E., McElroy, S.L. Frequency of NMS in a large psychiatric hopsital. American Journal of Psychiatry 1986; 143:1227-1233. Google ScholarPrakash, R., Kelwala, S., Ban, T.A. Neurotoxicity with combined administration of lithium and a neuroleptic. Compr Psychiatry 1982; 23:567-571. Google ScholarQuality Assurance Associates. Legal aspects of nursing documentation and practice. Fairfield, CT: Author, 1990. Google ScholarReyes v Houston International Hospital et al. 1991, DC Harris Co, TX. No. 89-03053. Google ScholarRobinson, M. Neuroleptic malignant syndrome associated with metoclopramide. J Neurol Neurosurg Psychiatry 1985; 45:1304-1305. Google ScholarSakkas, P., Davis, J.M., Hua, J., Wang, Z. Pharmacotherapy of neuroleptic malignant syndrome. Psychiatric Annals 1991; 21:157-164. Google ScholarSchuchla, T.J., Herjanic, M. Neuroleptic malignant syndrome, bromocriptine and anticholinergic drugs. J Clin Psychiatry 1988; 49:283-284. Google ScholarShalev, A., Munitz, H. The neuroleptic malignant syndrome; agent and host interaction. Acta Psychiatr Scand 1986; 73:337-347. Google ScholarShalev, A., Hermesh. H., Munitz, H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 1989; 50:18-25. Google ScholarShriqui, C.L., Bradwejn, J., Jones, B.D. Tardive dyskinesia: Legal and preventive aspects. Can J Psychiatry 1990; 35:576-580. Google ScholarSternberg, D. Neuroleptic malignant syndrome: Facts and controversies. American Journal of Psychiatry 1987; 144:1104-1105. Google ScholarTancredi, L.R. Malpractice and tardive dyskinesia: A conceptual dilemma. J Clin Psychopharmacol 1988; 8:71-76. Google ScholarTippermas, A. Extrapyramidal disorders. Carrier Letter 1989; 139:1-4. Google ScholarWilson, H.S., Kneisl, C.R. Psychiatric nursing, 2nd ed. Menlo Park, CA: Addison-Wesley, 1984. Google Scholar Previous article Next article FiguresReferencesRelatedDetailsCited by Breeden R, Ford H, Chrisman C and Mascioli C (2017) Neuroleptic Malignant Syndrome Secondary to Metoclopramide Use in an Elderly Gastroenterologic Surgery Patient, Gastroenterology Nursing, 10.1097/SGA.0000000000000173, 40:2, (93-100), . ALLEN J (1998) A survey of psychiatric nurses' opinions of advanced practice roles in psychiatric nursing, Journal of Psychiatric and Mental Health Nursing, 10.1046/j.1365-2850.1998.560451.x, 5:6, (451-462), Online publication date: 1-Dec-1998. Blair D and Ramones V (1994) Psychopharmacologic Treatment of Anxiety, Journal of Psychosocial Nursing and Mental Health Services, 32:7, (49-53), Online publication date: 1-Jul-1994. Request Permissions InformationCopyright 2013, SLACK IncorporatedPDF download
Referência(s)